Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Cybin Inc (CYBN) Message Board

Study Finds Type 2 Diabetes More Prevalent in Thos

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 341
(Total Views: 244)
Posted On: 12/10/2021 5:17:21 PM
Avatar
Posted By: NetworkNewsWire
Study Finds Type 2 Diabetes More Prevalent in Those with Psychiatric Disorders

Diabetes is a common disease, with figures showing that about 6% of the global population is afflicted by the ailment. Since 1990, rates of the disease have been increasing, with estimates showing that this trend is expected to continue for at least two more decades. Now new research has found that type 2 diabetes is more common in individuals with psychiatric disorder, in comparison with other people.

The research was carried out by a team of researchers from the University of Southern Denmark, led by Nanna Lindekilde of the school’s psychology department. Its findings were reported in “Diabetologia.”

Psychiatric disorders are known to diminish an individual’s quality of life and are linked to heighted rates of mortality. It is believed that the increased mortality rates are partly caused by more accidents and suicides as well as by a higher risk of developing physical conditions associated with mental health issues, which include respiratory and cardiovascular ailments.

Prior research discovered that the prevalence of this type of diabetes was higher in individuals with major depressive disorder, bipolar disorder and schizophrenia, in comparison to the general populace.

For their study, the researchers carried out an extensive search of various e-databases of scientific papers, finding more than 30 systematic reviews based on 245 primary studies. The categories of the disorders assessed in the studies include eating disorder, anxiety disorder, substance-use disorder, depression, bipolar disorder, schizophrenia, dementia, sleep disorder, psychosis, intellectual disability and a group made up of different psychiatric disorders.

The researchers found that individuals suffering from sleep disorders had the highest type 2 diabetes rates, at 40%. The disease’s prevalence in other psychiatric disorders was 11% for patients with psychosis and bipolar disorder, 14% for those with anxiety disorders, 16% for individuals with substance use disorder, and 21% for those afflicted with binge-eating disorder.

In their report, the researchers highlighted that while individuals suffering from any of the disorders studied had higher chances of having type 2 diabetes in comparison to the general populace, more elaborate comparisons needed to be made between prevalence estimates to account for differences in study settings and population groups.

The researchers note in their conclusion that type 2 diabetes’ prevalence among people with psychiatric disorders suggests that the ailments have a shared vulnerability, adding that understanding the behavioral and biological factors driving increased prevalence of the disease in those with psychiatric disorders better will be critical in the development of effective strategies for patient management.

The study clearly shows how vital it is to address psychiatric disorders as soon as possible before additional complications set in, and that is why the work of companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), which are developing new medicines targeting mental disorders, deserve any support available.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer



(0)
(0)




Cybin Inc (CYBN) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us